Genesis MedTech Closes Tens of Millions of Dollars in New Funding Round

Genesis MedTech has closed a new round of financing of hundreds of millions of RMB (tens of millions of US dollars) led by Wuxi Capital Group and Wuxi Binhu Industrial Investment Development Group, followed by a prominent US medical device company, for product development at its Wuxi base and subsequent domestic and international commercialization.

Genesis’ product portfolio includes surgical, neurovascular, peripheral vascular, and cardiovascular products used by more than 2,000 large and medium-sized hospitals in China and exported to international markets such as Europe, America, and South Korea. Genesis MedTech has established several high-end R&D and production bases in China and is equipped with high-level production capacity in terms of manufacturing process and mass production scale, in line with global advanced medical technology enterprises.

Genesis MedTech covers the entire chain of medical device production, R&D, clinical, registration, and sales, and has become a leading medical device company in China with strong capabilities in industry integration, independent innovation and R&D, and international cooperation,” said Haiying Fu, Managing Director of Wuxi Capital Group.

en_GBEnglish (UK)